| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| MicroRNAs | 17 | 2024 | 918 | 4.330 |
Why?
|
| Laryngeal Neoplasms | 6 | 2016 | 91 | 2.620 |
Why?
|
| Biomarkers, Tumor | 12 | 2025 | 1686 | 2.500 |
Why?
|
| Prostatic Neoplasms | 19 | 2020 | 1587 | 2.300 |
Why?
|
| Neoplastic Stem Cells | 6 | 2016 | 348 | 1.700 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2015 | 763 | 1.520 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2020 | 1303 | 1.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 15 | 2017 | 2072 | 1.120 |
Why?
|
| RNA, Untranslated | 1 | 2025 | 114 | 0.870 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2025 | 61 | 0.870 |
Why?
|
| Gene Expression Profiling | 12 | 2024 | 1880 | 0.870 |
Why?
|
| Chordoma | 3 | 2013 | 19 | 0.870 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2015 | 196 | 0.850 |
Why?
|
| Mutation | 6 | 2019 | 6251 | 0.820 |
Why?
|
| Alternative Splicing | 2 | 2019 | 364 | 0.700 |
Why?
|
| Mutation, Missense | 3 | 2015 | 934 | 0.690 |
Why?
|
| SOXB1 Transcription Factors | 3 | 2015 | 62 | 0.680 |
Why?
|
| Transfection | 6 | 2015 | 1020 | 0.660 |
Why?
|
| rab3 GTP-Binding Proteins | 1 | 2019 | 7 | 0.610 |
Why?
|
| Optic Atrophy | 1 | 2019 | 49 | 0.580 |
Why?
|
| Abnormalities, Multiple | 4 | 2019 | 980 | 0.560 |
Why?
|
| Cataract | 1 | 2019 | 169 | 0.540 |
Why?
|
| Skin Abnormalities | 2 | 2014 | 35 | 0.530 |
Why?
|
| Microcephaly | 3 | 2019 | 354 | 0.530 |
Why?
|
| Machine Learning | 1 | 2020 | 345 | 0.500 |
Why?
|
| Receptors, Fibroblast Growth Factor | 4 | 2004 | 60 | 0.500 |
Why?
|
| Male | 40 | 2024 | 64993 | 0.500 |
Why?
|
| CHARGE Syndrome | 1 | 2015 | 8 | 0.490 |
Why?
|
| Up-Regulation | 6 | 2015 | 883 | 0.490 |
Why?
|
| Prostate | 3 | 2017 | 442 | 0.490 |
Why?
|
| Centrioles | 1 | 2015 | 6 | 0.480 |
Why?
|
| Tongue Neoplasms | 1 | 2015 | 29 | 0.480 |
Why?
|
| Neoplasms | 2 | 2025 | 2947 | 0.470 |
Why?
|
| RNA Splice Sites | 1 | 2015 | 99 | 0.470 |
Why?
|
| White Coat Hypertension | 1 | 2015 | 11 | 0.460 |
Why?
|
| Usher Syndromes | 1 | 2015 | 12 | 0.460 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 7 | 2018 | 1045 | 0.460 |
Why?
|
| Down-Regulation | 6 | 2015 | 684 | 0.460 |
Why?
|
| Saliva | 1 | 2015 | 133 | 0.460 |
Why?
|
| Cell Proliferation | 5 | 2015 | 2515 | 0.460 |
Why?
|
| Decision Making | 1 | 2020 | 693 | 0.450 |
Why?
|
| Hypogonadism | 1 | 2019 | 319 | 0.450 |
Why?
|
| Humans | 52 | 2025 | 132278 | 0.450 |
Why?
|
| alpha-Crystallin B Chain | 1 | 2014 | 2 | 0.450 |
Why?
|
| Dwarfism | 1 | 2015 | 104 | 0.440 |
Why?
|
| Cornea | 1 | 2019 | 597 | 0.430 |
Why?
|
| DNA Helicases | 1 | 2015 | 242 | 0.430 |
Why?
|
| Prognosis | 6 | 2025 | 5006 | 0.420 |
Why?
|
| Ephrin-B1 | 1 | 2013 | 9 | 0.420 |
Why?
|
| Foot Deformities | 1 | 2013 | 4 | 0.420 |
Why?
|
| Tyrosinemias | 1 | 2013 | 7 | 0.410 |
Why?
|
| Real-Time Polymerase Chain Reaction | 5 | 2020 | 543 | 0.410 |
Why?
|
| Middle Aged | 17 | 2024 | 28847 | 0.410 |
Why?
|
| Skull Base Neoplasms | 1 | 2013 | 36 | 0.400 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2012 | 12 | 0.400 |
Why?
|
| Tumor Cells, Cultured | 6 | 2016 | 1067 | 0.390 |
Why?
|
| Neutropenia | 1 | 2014 | 205 | 0.390 |
Why?
|
| Cochlea | 1 | 2013 | 89 | 0.380 |
Why?
|
| Lymph Nodes | 1 | 2014 | 388 | 0.380 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2012 | 106 | 0.370 |
Why?
|
| ROC Curve | 4 | 2020 | 598 | 0.370 |
Why?
|
| Limb Deformities, Congenital | 1 | 2013 | 112 | 0.370 |
Why?
|
| Case-Control Studies | 6 | 2024 | 3419 | 0.370 |
Why?
|
| Lymphocytes | 1 | 2013 | 369 | 0.360 |
Why?
|
| Intellectual Disability | 1 | 2019 | 1094 | 0.360 |
Why?
|
| Craniofacial Abnormalities | 1 | 2013 | 252 | 0.350 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2013 | 156 | 0.350 |
Why?
|
| Neoplasm Proteins | 2 | 2014 | 703 | 0.340 |
Why?
|
| Proteins | 2 | 2015 | 1066 | 0.330 |
Why?
|
| Phenotype | 5 | 2019 | 4542 | 0.310 |
Why?
|
| Female | 24 | 2024 | 70773 | 0.300 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 1810 | 0.300 |
Why?
|
| Pedigree | 4 | 2019 | 1725 | 0.300 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 615 | 0.300 |
Why?
|
| Prostatectomy | 3 | 2020 | 356 | 0.290 |
Why?
|
| Prenatal Diagnosis | 1 | 2012 | 634 | 0.280 |
Why?
|
| Cell Cycle Proteins | 3 | 2015 | 686 | 0.280 |
Why?
|
| DNA-Binding Proteins | 2 | 2015 | 2067 | 0.270 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2004 | 53 | 0.260 |
Why?
|
| Adult | 13 | 2024 | 31585 | 0.260 |
Why?
|
| Bone Neoplasms | 1 | 2011 | 445 | 0.260 |
Why?
|
| Cell Line, Tumor | 7 | 2015 | 3700 | 0.250 |
Why?
|
| Turkey | 2 | 2019 | 67 | 0.250 |
Why?
|
| Genes, Dominant | 2 | 2004 | 250 | 0.250 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 1294 | 0.240 |
Why?
|
| AC133 Antigen | 2 | 2016 | 37 | 0.240 |
Why?
|
| cdc25 Phosphatases | 1 | 2005 | 20 | 0.240 |
Why?
|
| Liquid Biopsy | 1 | 2025 | 16 | 0.230 |
Why?
|
| Genetic Therapy | 2 | 2014 | 720 | 0.230 |
Why?
|
| Apoptosis | 5 | 2015 | 1907 | 0.220 |
Why?
|
| Aged | 8 | 2015 | 21347 | 0.220 |
Why?
|
| Adenoviridae | 2 | 2004 | 596 | 0.210 |
Why?
|
| Electroconvulsive Therapy | 1 | 2024 | 82 | 0.200 |
Why?
|
| Antineoplastic Agents | 2 | 2011 | 1828 | 0.190 |
Why?
|
| Blotting, Western | 3 | 2015 | 1086 | 0.190 |
Why?
|
| RNA, Long Noncoding | 1 | 2025 | 241 | 0.190 |
Why?
|
| Schizophrenia | 1 | 2024 | 332 | 0.170 |
Why?
|
| Tissue Kallikreins | 1 | 2020 | 7 | 0.170 |
Why?
|
| Normal Distribution | 1 | 2020 | 20 | 0.170 |
Why?
|
| Signal Transduction | 5 | 2020 | 4737 | 0.160 |
Why?
|
| Exome | 2 | 2015 | 1086 | 0.160 |
Why?
|
| Probability | 1 | 2020 | 323 | 0.160 |
Why?
|
| Infant | 8 | 2016 | 13177 | 0.160 |
Why?
|
| Genes, p53 | 1 | 2020 | 222 | 0.160 |
Why?
|
| Disease Progression | 3 | 2015 | 2228 | 0.150 |
Why?
|
| INDEL Mutation | 1 | 2019 | 92 | 0.150 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2020 | 259 | 0.150 |
Why?
|
| RNA, Neoplasm | 1 | 2018 | 140 | 0.140 |
Why?
|
| Child | 8 | 2019 | 25777 | 0.140 |
Why?
|
| Child, Preschool | 7 | 2016 | 14831 | 0.140 |
Why?
|
| Siblings | 1 | 2019 | 202 | 0.140 |
Why?
|
| Area Under Curve | 2 | 2015 | 319 | 0.130 |
Why?
|
| Homozygote | 1 | 2019 | 548 | 0.130 |
Why?
|
| DNA Damage | 1 | 2020 | 513 | 0.130 |
Why?
|
| Multivariate Analysis | 1 | 2020 | 1442 | 0.130 |
Why?
|
| Receptors, Oxytocin | 1 | 2016 | 21 | 0.130 |
Why?
|
| Melanoma | 1 | 2004 | 954 | 0.130 |
Why?
|
| Gene Expression Regulation | 3 | 2015 | 2492 | 0.130 |
Why?
|
| Flow Cytometry | 2 | 2013 | 806 | 0.120 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 896 | 0.120 |
Why?
|
| Serum Globulins | 1 | 2015 | 7 | 0.120 |
Why?
|
| Mannose-Binding Protein-Associated Serine Proteases | 1 | 2015 | 1 | 0.120 |
Why?
|
| Heterozygote | 2 | 2015 | 718 | 0.120 |
Why?
|
| Phorbols | 1 | 2015 | 5 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2020 | 773 | 0.120 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2015 | 45 | 0.120 |
Why?
|
| Spheroids, Cellular | 1 | 2015 | 63 | 0.120 |
Why?
|
| Platelet Count | 1 | 2015 | 140 | 0.120 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2015 | 97 | 0.120 |
Why?
|
| Hep G2 Cells | 1 | 2015 | 94 | 0.120 |
Why?
|
| Cell Survival | 4 | 2012 | 869 | 0.120 |
Why?
|
| G1 Phase | 1 | 2015 | 66 | 0.120 |
Why?
|
| Preoperative Period | 1 | 2015 | 92 | 0.110 |
Why?
|
| De Lange Syndrome | 1 | 2015 | 45 | 0.110 |
Why?
|
| RNA Interference | 1 | 2016 | 519 | 0.110 |
Why?
|
| Hepatitis B, Chronic | 1 | 2015 | 85 | 0.110 |
Why?
|
| Cell Division | 4 | 2004 | 748 | 0.110 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2014 | 45 | 0.110 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 3018 | 0.110 |
Why?
|
| Microarray Analysis | 1 | 2015 | 237 | 0.110 |
Why?
|
| Gold | 1 | 2014 | 57 | 0.110 |
Why?
|
| Cell Differentiation | 4 | 2011 | 1990 | 0.110 |
Why?
|
| MCF-7 Cells | 1 | 2014 | 217 | 0.110 |
Why?
|
| Phosphotransferases | 1 | 2014 | 40 | 0.110 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2015 | 243 | 0.110 |
Why?
|
| Codon, Nonsense | 1 | 2015 | 144 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 2 | 2016 | 1344 | 0.110 |
Why?
|
| Metal Nanoparticles | 1 | 2014 | 57 | 0.110 |
Why?
|
| Postoperative Period | 1 | 2015 | 333 | 0.110 |
Why?
|
| Cell Movement | 2 | 2015 | 894 | 0.110 |
Why?
|
| Fibroblasts | 2 | 2015 | 879 | 0.110 |
Why?
|
| Retinitis Pigmentosa | 1 | 2015 | 96 | 0.110 |
Why?
|
| HeLa Cells | 1 | 2015 | 762 | 0.110 |
Why?
|
| Cytoskeletal Proteins | 1 | 2015 | 281 | 0.110 |
Why?
|
| RNA, Transfer | 1 | 2014 | 69 | 0.110 |
Why?
|
| Hyaluronan Receptors | 1 | 2014 | 62 | 0.110 |
Why?
|
| Immunohistochemistry | 3 | 2014 | 1723 | 0.100 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 234 | 0.100 |
Why?
|
| Prostatic Hyperplasia | 1 | 2014 | 117 | 0.100 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2014 | 120 | 0.100 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 826 | 0.100 |
Why?
|
| RNA, Messenger | 2 | 2013 | 2714 | 0.100 |
Why?
|
| Oncogenes | 1 | 2014 | 176 | 0.100 |
Why?
|
| Central Nervous System Diseases | 1 | 2014 | 109 | 0.100 |
Why?
|
| Cutis Laxa | 1 | 2013 | 10 | 0.100 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 7102 | 0.100 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2014 | 210 | 0.100 |
Why?
|
| Cell Separation | 1 | 2014 | 227 | 0.100 |
Why?
|
| Gene Regulatory Networks | 1 | 2015 | 382 | 0.100 |
Why?
|
| Prostate-Specific Antigen | 1 | 2014 | 272 | 0.100 |
Why?
|
| Karyotype | 1 | 2013 | 31 | 0.100 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 443 | 0.100 |
Why?
|
| Algorithms | 1 | 2020 | 1718 | 0.100 |
Why?
|
| CDC2 Protein Kinase | 2 | 2004 | 36 | 0.100 |
Why?
|
| Exons | 1 | 2015 | 806 | 0.100 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2014 | 137 | 0.100 |
Why?
|
| Ichthyosis | 1 | 2012 | 29 | 0.100 |
Why?
|
| Hashimoto Disease | 1 | 2013 | 29 | 0.100 |
Why?
|
| Hearing Loss | 1 | 2015 | 212 | 0.100 |
Why?
|
| Dermatitis | 1 | 2012 | 28 | 0.100 |
Why?
|
| Lymphocyte Count | 1 | 2012 | 120 | 0.100 |
Why?
|
| Hamartoma | 1 | 2013 | 52 | 0.100 |
Why?
|
| Neoplasm Staging | 2 | 2014 | 1366 | 0.100 |
Why?
|
| Chromosome Aberrations | 1 | 2015 | 591 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 665 | 0.090 |
Why?
|
| Skin | 1 | 2015 | 540 | 0.090 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 956 | 0.090 |
Why?
|
| Stem Cells | 2 | 2007 | 737 | 0.090 |
Why?
|
| Cluster Analysis | 1 | 2013 | 436 | 0.090 |
Why?
|
| Antigens, CD | 1 | 2014 | 437 | 0.090 |
Why?
|
| Immunoglobulin E | 1 | 2012 | 180 | 0.090 |
Why?
|
| Imatinib Mesylate | 1 | 2011 | 48 | 0.090 |
Why?
|
| Cohort Studies | 2 | 2018 | 5145 | 0.090 |
Why?
|
| Vidarabine | 1 | 2011 | 80 | 0.090 |
Why?
|
| Nanoparticles | 1 | 2014 | 288 | 0.090 |
Why?
|
| Glycoproteins | 1 | 2014 | 378 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 1561 | 0.090 |
Why?
|
| Nervous System Diseases | 1 | 2015 | 410 | 0.090 |
Why?
|
| Etoposide | 1 | 2011 | 120 | 0.090 |
Why?
|
| Amino Acid Sequence | 1 | 2015 | 2696 | 0.090 |
Why?
|
| Amino Acid Substitution | 1 | 2012 | 409 | 0.090 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 729 | 0.090 |
Why?
|
| Pilot Projects | 1 | 2015 | 1452 | 0.090 |
Why?
|
| Base Sequence | 1 | 2015 | 2990 | 0.090 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2012 | 72 | 0.090 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2011 | 104 | 0.090 |
Why?
|
| Benzamides | 1 | 2011 | 124 | 0.090 |
Why?
|
| Autism Spectrum Disorder | 1 | 2016 | 429 | 0.090 |
Why?
|
| Vincristine | 1 | 2011 | 195 | 0.090 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2011 | 128 | 0.080 |
Why?
|
| Genome-Wide Association Study | 2 | 2015 | 1829 | 0.080 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 3838 | 0.080 |
Why?
|
| Rare Diseases | 1 | 2013 | 208 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2014 | 1569 | 0.080 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2012 | 234 | 0.080 |
Why?
|
| Recurrence | 1 | 2014 | 1458 | 0.080 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 412 | 0.080 |
Why?
|
| Peptides | 1 | 2014 | 842 | 0.080 |
Why?
|
| Killer Cells, Natural | 1 | 2012 | 353 | 0.080 |
Why?
|
| Doxorubicin | 1 | 2011 | 303 | 0.080 |
Why?
|
| Cisplatin | 1 | 2011 | 281 | 0.080 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2011 | 195 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2012 | 449 | 0.080 |
Why?
|
| Piperazines | 1 | 2011 | 253 | 0.080 |
Why?
|
| Cell Lineage | 1 | 2011 | 362 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2016 | 1132 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2015 | 3071 | 0.080 |
Why?
|
| Family | 1 | 2012 | 596 | 0.080 |
Why?
|
| Methotrexate | 1 | 2011 | 351 | 0.080 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 760 | 0.070 |
Why?
|
| Ki-67 Antigen | 2 | 2006 | 119 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 1963 | 0.070 |
Why?
|
| Genetic Variation | 1 | 2015 | 1583 | 0.070 |
Why?
|
| Liver Cirrhosis | 1 | 2015 | 897 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2011 | 417 | 0.070 |
Why?
|
| Genotype | 1 | 2014 | 2704 | 0.070 |
Why?
|
| Transcriptome | 1 | 2015 | 1126 | 0.070 |
Why?
|
| Computational Biology | 1 | 2013 | 874 | 0.070 |
Why?
|
| Microspheres | 1 | 2007 | 74 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 1295 | 0.070 |
Why?
|
| Cartilage | 1 | 2007 | 51 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2014 | 2849 | 0.070 |
Why?
|
| Adipocytes, Brown | 1 | 2007 | 28 | 0.070 |
Why?
|
| Somatomedins | 1 | 2006 | 35 | 0.070 |
Why?
|
| Chondrogenesis | 1 | 2007 | 28 | 0.070 |
Why?
|
| Chondrocytes | 1 | 2007 | 51 | 0.060 |
Why?
|
| Ossification, Heterotopic | 1 | 2007 | 38 | 0.060 |
Why?
|
| Neurites | 1 | 2006 | 46 | 0.060 |
Why?
|
| Time Factors | 4 | 2006 | 6454 | 0.060 |
Why?
|
| Ganglia, Spinal | 1 | 2006 | 69 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2011 | 817 | 0.060 |
Why?
|
| Transcription Factor AP-1 | 1 | 2006 | 111 | 0.060 |
Why?
|
| Osteogenesis | 1 | 2007 | 163 | 0.060 |
Why?
|
| Histone Acetyltransferases | 1 | 2006 | 238 | 0.060 |
Why?
|
| Monocytes | 1 | 2007 | 345 | 0.060 |
Why?
|
| Trans-Activators | 2 | 2006 | 746 | 0.060 |
Why?
|
| Infant, Newborn | 2 | 2015 | 8558 | 0.060 |
Why?
|
| Isoenzymes | 1 | 2005 | 222 | 0.060 |
Why?
|
| Breast Neoplasms | 2 | 2014 | 2686 | 0.050 |
Why?
|
| G2 Phase | 1 | 2004 | 43 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2014 | 2572 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2004 | 88 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2006 | 505 | 0.050 |
Why?
|
| Sialoglycoproteins | 1 | 2003 | 44 | 0.050 |
Why?
|
| Oxygen | 1 | 2007 | 572 | 0.050 |
Why?
|
| Cyclins | 1 | 2004 | 102 | 0.050 |
Why?
|
| Fibroblast Growth Factors | 1 | 2004 | 163 | 0.050 |
Why?
|
| Brain | 1 | 2015 | 3193 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2003 | 92 | 0.050 |
Why?
|
| Animals | 8 | 2014 | 35136 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2003 | 148 | 0.050 |
Why?
|
| Cytogenetics | 1 | 2001 | 16 | 0.050 |
Why?
|
| Cyclin B1 | 1 | 2001 | 8 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2001 | 147 | 0.050 |
Why?
|
| Cyclin B | 1 | 2001 | 23 | 0.050 |
Why?
|
| Lac Operon | 1 | 2001 | 92 | 0.050 |
Why?
|
| Chromosomes | 1 | 2001 | 140 | 0.040 |
Why?
|
| Cell Death | 1 | 2001 | 242 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2007 | 1041 | 0.040 |
Why?
|
| DNA, Neoplasm | 1 | 2020 | 296 | 0.040 |
Why?
|
| Pregnancy | 1 | 2012 | 7563 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2001 | 438 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2015 | 17344 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2001 | 611 | 0.040 |
Why?
|
| Mice | 7 | 2014 | 18622 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 3355 | 0.030 |
Why?
|
| Mice, Inbred NOD | 2 | 2007 | 317 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2003 | 1019 | 0.030 |
Why?
|
| Globulins | 1 | 2015 | 4 | 0.030 |
Why?
|
| Mice, SCID | 2 | 2007 | 606 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2015 | 127 | 0.030 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2015 | 29 | 0.030 |
Why?
|
| Exonucleases | 1 | 2015 | 25 | 0.030 |
Why?
|
| Mice, Inbred CBA | 1 | 2014 | 29 | 0.030 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2015 | 74 | 0.030 |
Why?
|
| Histone Deacetylases | 1 | 2015 | 123 | 0.030 |
Why?
|
| Cerebrum | 1 | 2014 | 37 | 0.030 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2015 | 172 | 0.030 |
Why?
|
| Endoribonucleases | 1 | 2014 | 85 | 0.030 |
Why?
|
| Hypertelorism | 1 | 2013 | 11 | 0.030 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2015 | 202 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2015 | 499 | 0.020 |
Why?
|
| Corpus Callosum | 1 | 2013 | 104 | 0.020 |
Why?
|
| Syndrome | 1 | 2015 | 1171 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 311 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 3 | 2007 | 4773 | 0.020 |
Why?
|
| Biopsy | 1 | 2015 | 1287 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 853 | 0.020 |
Why?
|
| Adolescent | 3 | 2015 | 20510 | 0.020 |
Why?
|
| Craniosynostoses | 1 | 2013 | 134 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2015 | 825 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2014 | 605 | 0.020 |
Why?
|
| Young Adult | 2 | 2015 | 9936 | 0.020 |
Why?
|
| Phosphorylation | 2 | 2003 | 1610 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 637 | 0.020 |
Why?
|
| Liver | 1 | 2015 | 1816 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2009 | 305 | 0.020 |
Why?
|
| 3T3 Cells | 1 | 2007 | 126 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2009 | 449 | 0.020 |
Why?
|
| Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein | 1 | 2006 | 4 | 0.020 |
Why?
|
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 1 | 2006 | 13 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2006 | 3888 | 0.020 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2006 | 35 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2007 | 101 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2007 | 87 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2006 | 125 | 0.020 |
Why?
|
| Myeloid Cells | 1 | 2007 | 119 | 0.020 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2006 | 78 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2006 | 239 | 0.020 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2007 | 127 | 0.020 |
Why?
|
| Biomarkers | 1 | 2015 | 3388 | 0.020 |
Why?
|
| Caspases | 1 | 2006 | 165 | 0.020 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2006 | 264 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2004 | 92 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 2007 | 4681 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2006 | 447 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2007 | 478 | 0.010 |
Why?
|
| Fibroblast Growth Factor 1 | 1 | 2003 | 15 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 578 | 0.010 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2003 | 38 | 0.010 |
Why?
|
| Osteopontin | 1 | 2003 | 51 | 0.010 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2003 | 70 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2003 | 384 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2003 | 241 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2003 | 616 | 0.010 |
Why?
|
| Cell Line | 1 | 2007 | 2759 | 0.010 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2001 | 43 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 1530 | 0.010 |
Why?
|
| Growth Substances | 1 | 2001 | 110 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2003 | 444 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 2006 | 729 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2001 | 829 | 0.010 |
Why?
|
| STAT3 Transcription Factor | 1 | 2001 | 232 | 0.010 |
Why?
|
| Alleles | 1 | 2003 | 1680 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2001 | 1674 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2001 | 906 | 0.010 |
Why?
|